Case Study Of Hiv Aids Patient

Please, wait while we are validating your browser

1. Alvar J, Cañavate C, Gutiérrez-Solar B, Jiménez M, Laguna F, López-Vélez R, et al. Leishmania and human immunodeficiency virus coinfection: the first 10 years. Clin Microbiol Rev. 1997;10:298–319.[PMC free article][PubMed]

2. Badaró R, Carvalho EM, Rocha H, Queiroz AC, Jones TC. Leishmania donovani: an opportunistic microbe associated with progressive disease in three immunocompromised patients. Lancet. 1986;1((8482)):647–8.[PubMed]

3. Berenguer J, Cosin J, Miralles P, López JC, Padilla B. Discontinuation of secondary anti-Leishmania prophylaxis in HIV-infected patients who have responded to highly active antiretroviral therapy. AIDS. 2000;14:2946–8.[PubMed]

4. Bittencourt A, Silva N, Straatmann A, Nunes VL, Follador I, Badaró R. Post kala-azar dermal leishmaniasis associated with AIDS. Braz J Infect Dis. 2002;6:313–6.[PubMed]

5. Bourgeois N, Bastien P, Reynes J, Makinson A, Rouanet I, Lachaud L. ‘Active chronic visceral leishmaniasis’ in HIV-1-infected patients demonstrated by biological and clinical long-term follow-up of 10 patients. HIV Med. 2010;11:670–3.[PubMed]

6. Bourgeois N, Lachaud L, Reynes J, Rouanet I, Mahamat A, Bastien P. Long-term monitoring of visceral leishmaniasis in patients with AIDS: relapse risk factors, value of polymerase chain reaction, and potential impact on secondary prophylaxis. J Acquir Immune Defic Syndr. 2008;48:13–9.[PubMed]

7. Brasil . Brasília: Ministério da Saúde; 2011. Ministério da Saúde. Secretaria de Vigilância em Saúde. Manual de recomendações para diagnóstico, tratamento e acompanhamento de pacientes com a coinfecção Leishmania-HIV.

8. Brasil Ministério da Saúde. Secretaria de Vigilância em Saúde. Aids no Brasil. Epidemia concentrada e estabilizada em populações de maior vulnerabilidade. Bol Epidemiol AIDS/DST. 2011;8((1)):10–5.

9. Casado JL, Lopez-Velez R, Pintado V, Quereda C, Antela A, Moreno S. Relapsing visceral leishmaniasis in HIV-infected patients undergoing successful protease inhibitor therapy. Eur J Clin Microbiol Infect Dis. 2001;20:202–5.[PubMed]

10. Cavalcanti ATA, Medeiros Z, Lopes F, Andrade L, Ferreira VM, Magalhães V, et al. Diagnosing visceral leishmaniasis and HIV/AIDS co-infection: a case series study in Pernambuco, Brazil. Rev Inst Med Trop Sao Paulo. 2012;54:43–7.[PubMed]

11. Cota GF, Sousa MR, Rabello A. Predictors of visceral leishmaniasis relapse in HIV patients: a systematic review. PLoS Negl Trop Dis. 2011;5((6)):e1153.[PMC free article][PubMed]

12. Cruz I, Nieto J, Moreno J, Cañavate C, Desjeux P, Alvar J. Leishmania/HIV co- infections in the second decade. Indian J Med Res. 2006;123:357–88.[PubMed]

13. Daher EF, Fonseca PP, Gerhard ES, Leitão TM, Silva Júnior GB. Clinical and epidemiological features of visceral leishmaniasis and HIV co-infection in fifteen patients from Brazil. J Parasitol. 2009;95:652–5.[PubMed]

14. Fernández Cotarelo MJ, Abellán Martínez J, Guerra Vales JM, Martínez Sánchez P, Rodrigo Gómez De La Bárcena M, Salto Fernández E. Effect of highly active antiretroviral therapy on the incidence and clinical manifestations of visceral leishmaniasis in human immunodeficiency virus-infected patients. Clin Infect Dis. 2003;37:973–7.[PubMed]

15. Hailu A. Pre- and post-treatment antibody levels in visceral leishmaniasis. Trans R Soc Trop Med Hyg. 1990;84:673–5.[PubMed]

16. Kubar J, Marty P, Lelièvre A, Quaranta JF, Staccini P, Caroli-Bosc C, et al. Visceral leishmaniosis in HIV-positive patients: primary infection, reactivation and latent infection. Impact of the CD4+ T-lymphocyte counts. AIDS. 1998;12:2147–53.[PubMed]

17. Lopez-Velez R, Perez-Molina JA, Guerrero A, Baquero F, Villarrubia J, Escribano L, et al. Clinicoepidemiologic characteristics, prognostic factors, and survival analysis of patients coinfected with human immunodeficiency virus and Leishmania in an area of Madrid, Spain. Am J Trop Med Hyg. 1998;58:436–43.[PubMed]

18. Maia-Elkhoury AN, Alves WA, Sousa-Gomes ML, Sena JM, Luna EA. Visceral leishmaniasis in Brazil: trends and challenges. Cad Saúde Pública. 2008;24:2941–7.[PubMed]

19. Marfurt J, Niederwieser I, Makia ND, Beck HP, Felger I. Diagnostic genotyping of Old and New World Leishmania species by PCR- RFLP. Diagn Microbiol Infect Dis. 2003;46:115–24.[PubMed]

20. Morales MA, Cruz I, Rubio JM, Chicharro C, Cañavate C, Laguna F, et al. Relapses versus reinfections in patients coinfected with Leishmania infantum and human immunodeficiency virus type 1. J Infect Dis. 2002;185:1533–7.[PubMed]

21. Orsini M, Silva M, Luz ZM, Disch J, Fernandes O, Moreira D, et al. Identification of Leishmania chagasi from skin in Leishmania/HIV co-infection: a case report. Rev Soc Bras Med Trop. 2002;35:259–62.[PubMed]

22. Pintado V, Martín-Rabadán P, Rivera ML, Moreno S, Bouza E. Visceral leishmaniasis in human immunodeficiency virus (HIV)-infected and non-HIV infected patients. Medicine (Baltimore) 2001;80:54–73.[PubMed]

23. Prata A, Domingues A. Leishmanióide dérmico. O Hospital. 1955;50:93–113.

24. Rosenthal E, Marty P, del Giudice P, Pradier C, Ceppi C, Gastaut JA, et al. HIV and Leishmania coinfection: a review of 91 cases with focus on atypical locations of Leishmania . Clin Infect Dis. 2000;31:1093–5.[PubMed]

25. Russo R, Laguna F, López-Vélez R, Medrano FJ, Rosenthal E, Cacopardo B, et al. Visceral leishmaniasis in those infected with HIV: clinical aspects and other opportunistic infections. Ann Trop Med Parasitol. 2003;97((Suppl 1)):S99–S105.[PubMed]

26. Schonian G, Nasereddin A, Dinse N, Schweynoch C, Schallig HD, Presber W, et al. PCR diagnosis and characterization of Leishmania in local and imported clinical samples. Diagn Microbiol Infect Dis. 2003;47:349–58.[PubMed]

27. World Health Organization . Geneva: World Health Organization; 2007. 5th Consultative Meeting on Leishmania/HIV Coinfection; 2007 Mar 20-22; Addis Ababa, ET.

28. Zijlstra EE, Musa AM, Khalil EA, el-Hassan IM, el-Hassan AM. Post kala-azar dermal leishmaniasis. Lancet Infect Dis. 2003;3:87–98.[PubMed]

One thought on “Case Study Of Hiv Aids Patient

Leave a Reply

Your email address will not be published. Required fields are marked *